64 results
8-K
EX-10.1
HEPA
Hepion Pharmaceuticals Inc
2 Oct 23
Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rules
6:29pm
” transaction. The Company further understands and acknowledges that (y) one or more Purchasers may engage in hedging activities (in material compliance … the periods that the value of the Warrant Shares deliverable with respect to Warrants are being determined, and (z) such hedging activities (if any) could
424B5
HEPA
Hepion Pharmaceuticals Inc
2 Oct 23
Prospectus supplement for primary offering
4:52pm
and investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities
8-K
EX-10.1
fcll97zx870zu
8 Nov 22
Hepion Pharmaceuticals Announces Pricing of $20.0 Million Private Placement of Convertible Redeemable Preferred Stock
8:41pm
8-K
EX-10.2
dzi7ap82b1 dym705
8 Nov 22
Hepion Pharmaceuticals Announces Pricing of $20.0 Million Private Placement of Convertible Redeemable Preferred Stock
8:41pm
424B5
mkpzbqnt2yr 6a6e
16 Feb 21
Prospectus supplement for primary offering
5:11pm
424B5
0sh49m9nntl2g9zef
16 Feb 21
Prospectus supplement for primary offering
6:03am